The short answer
Maridebart cafraglutide is in a multi-trial Phase 3 programme under the MARITIME name, registered across obesity, obstructive sleep apnoea and heart failure indications. The heart failure trial alone enrols 5,056 participants.
Key facts
- MARITIME-HF
- NCT07037459, recruiting, n=5,056
- MARITIME-OSA-2
- NCT07226765, active not recruiting, n=250
- MARITIME-3-J
- NCT06987695, active not recruiting, n=279
- Phase
- 3, all of the above
- Registry checked
- ClinicalTrials.gov, 21 November 2026
- Phase 2 readout
- NEJM, 4 September 2025
- Authorisation
- None (investigational)
What the programme covers
More than weight. The registered Phase 3 trials verified on ClinicalTrials.gov span obesity, obstructive sleep apnoea and heart failure with preserved or mildly reduced ejection fraction. A compound entering Phase 3 across three organ-system indications simultaneously is being developed as a metabolic agent from the outset.
The scale of the heart failure trial
MARITIME-HF, NCT07037459, is recruiting 5,056 participants. That is larger than most obesity trials in this field and comparable to a dedicated cardiovascular outcome programme. Enrolment on that scale is committed only where the endpoint requires it, which points to hard clinical events rather than a surrogate.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why sleep apnoea appears here too
Obstructive sleep apnoea is strongly associated with obesity, and tirzepatide has already been studied in it. A second compound entering the same indication indicates the field regards it as an established rather than speculative extension of incretin pharmacology.
Why regional trials appear separately
MARITIME-3-J is a separate registration with 279 participants. Regional trials exist because regulators in some jurisdictions require data in their own populations, and because BMI thresholds and body composition differ enough that a global trial does not automatically answer a local question.
What Phase 3 breadth does not establish
Efficacy. A large multi-indication Phase 3 programme reflects a sponsor's assessment that Phase 2 justified the investment. Jastreboff and colleagues published that Phase 2 in the New England Journal of Medicine in September 2025. Compounds enter Phase 3 across several indications and fail, and the programme is the question rather than the answer.
Current status
Maridebart cafraglutide holds no marketing authorisation anywhere and is available only within registered clinical trials. Nothing supplied here is related to it, and no research material is an alternative to any investigational or licensed medicine.
Frequently asked questions
What indications is MariTide being tested in?
Obesity, obstructive sleep apnoea, and heart failure with preserved or mildly reduced ejection fraction, across registered Phase 3 trials.
Is it approved anywhere?
No. It is investigational and available only within registered clinical trials.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · MARITIME-HF (NCT07037459)clinicaltrials.gov
- TrialClinicalTrials.gov · MARITIME-OSA-2 (NCT07226765)clinicaltrials.gov
- TrialClinicalTrials.gov · MARITIME-3-J (NCT06987695)clinicaltrials.gov
- PubMedJastreboff AM et al., Once-Monthly Maridebart Cafraglutide: A Phase 2 Trial. NEJM 2025 (PMID 40549887)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Reading a Programme From Its Trial RegistrationsOne trial was withdrawn with zero enrolment; three others are completed, active or recruiting. Withdrawn and terminated mean different things.
- What the Systematic Reviews Say About Children and AdolescentsTwo 2025 systematic reviews assessed GLP-1 agonists in children and adolescents. What review-level evidence establishes, and what is still missing.
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD - and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.